How shall we use the proteomics toolbox for biomarker discovery?

被引：122

作者：

Lescuyer, Pierre

Hochstrasser, Denis

Rabilloud, Thierry ^{[1
]}

机构：

[1] Univ Geneva, Fac Sci, Fac Med, Dept Stuct Biol & Bioinformat, Geneva, Switzerland

[2] Univ Geneva, Fac Sci, Fac Med, Pharm Sect, Geneva, Switzerland

[3] Univ Geneva, Dept Genet, Lab Med Serv, Lab Med, CH-1211 Geneva, Switzerland

[4] BBSI, CEA, DSV, iRTSV, F-38054 Grenoble 9, France

[5] CNRS, UMR 5092, F-38054 Grenoble 9, France

来源：

JOURNAL OF PROTEOME RESEARCH | 2007年 / 6卷 / 09期

关键词：

proteomics; biomarkers; plasma; biological fluids; cerebrospinal fluid;

D O I：

10.1021/pr0702060

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Biomarker discovery for clinical purposes is one of the major areas in which proteomics is used. However, despite considerable effort, the successes have been relatively scarce. In this perspective paper, we try to highlight and analyze the main causes for this limited success, and to suggest alternate strategies, which will avoid them, without eluding the foreseeable weak points of these strategies. Two major strategies are analyzed, namely, the switch from body fluids to cell and tissues for the initial biomarker discovery step or, if body fluids must be analyzed, the implementation of highly selective protein selection strategies.

引用

页码：3371 / 3376

页数：6

共 38 条

[31] Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis [J].